paul bromann

Managed the Centre for Drug Research (CDR) at the University of Helsinki. Responsible for facilitating patenting and technology transfer of CDR discoveries in drug discovery and pharmaceutical technologies. Lead CDR promotion and outreach to external stakeholders. Developed strategic partnerships and managed international consortia to support fundraising, and managed CDR research projects. Managed IP value creation through collaboration with domestic and international industry, academia, and government organizations. Developed CDR strategic vision and led execution of CDR strategic goals; manage CDR IP portfolio and administrative budget.

* Led preclinical research and development of ANSX109/142, a recombinant protein antiviral therapeutic. Led ANSX109/142 protein engineering efforts to improve target selectivity and production. Evaluated ANSX109/142 efficacy and safety in cell culture and in animal model systems. Core member of group interacting with internal R&D teams and with contract research organizations. * Led the in vitro research efforts to identify novel antiviral drug target * Managed protein engineering methods to improve protein substrate selectivity * Led high-throughput enzyme activity screening * Designed and managed recombinant protein production processes * Developed purification protocol for protein production * Developed enzyme activity assays to qualify production lots * Designed and managed drug efficacy, pharmokinetics, and toxicity studies

* Led investigation of Src family kinases (SFK) in cancer signaling. Led studies of SFKs and SFK substrates in regulating cell motility, cancer cell metastasis and invasion. Discovered, cloned, and characterized Tks4 (SH3PXD2B), a novel SFK substrate involved in cancer cell migration and invasion. Identified growth-factor-induced expression of specific genes regulated by SFK activity, and discovered SFK mechanism for regulating mRNA stability. * Combined Affymetrix genearray and kinase inhibitors to characterize SFK signaling * Identified discrete sets of genes that are expressed in response to PDGF specifically through Src, MEK or PI3-K * Discovered a role for SFKs in regulating PDGF-induced RNA stability through p53 * Discovered, cloned, and characterized a novel SFK substrate called Tks4 * Developed a novel podosome formation assay to demonstrate role for Tks4 in regulating formation of podosomes * Developed Tks4 and Tks5 knockdown zebrafish strains using morpholinos and characterized mutant phenotypes

* Led investigation of Src family kinases (SFK) in cancer signaling. Led studies of SFKs and SFK substrates in regulating cell motility, cancer cell metastasis and invasion. Discovered, cloned, and characterized Tks4 (SH3PXD2B), a novel SFK substrate involved in cancer cell migration and invasion. Identified growth-factor-induced expression of specific genes regulated by SFK activity, and discovered SFK mechanism for regulating mRNA stability. * Combined Affymetrix genearray and kinase inhibitors to characterize SFK signaling * Identified discrete sets of genes that are expressed in response to PDGF specifically through Src, MEK or PI3-K * Discovered a role for SFKs in regulating PDGF-induced RNA stability through p53 * Discovered, cloned, and characterized a novel SFK substrate called Tks4 * Developed a novel podosome formation assay to demonstrate role for Tks4 in regulating formation of podosomes * Developed Tks4 and Tks5 knockdown zebrafish strains using morpholinos and characterized mutant phenotypes

I lead the Scientific Affairs function at Illumina - a leading developer, manufacturer, and marketer of life science tools and integrated systems for large-scale analysis of genetic variation and function. I manage a team of scientists that leverage internal and external scientific expertise to create digital content and services that drive genomics awareness and knowledge. I also created and currently host the Illumina Genomics Podcast, a show featuring thought leader interviews that illustrate the impact of genomics on science and medicine.

As a Clinical Educator Liaison at BMS, I was primarily responsible for conducting presentations to health care professionals (HCPs) of approved Orencia efficacy and safety information, identified and prioritized in collaboration with BMS commercial field force. I accurately responded to on-label and off-label medical questions from HCPs in accordance with approved BMS guidance and applicable laws, regulations and ethical standards. I also communicated information on autoimmune diseases and drug mechanism of action.

Led a multidisciplinary team in discovering and engineering novel industrial enzyme biocatalysts for production of lignocellulosic biofuels. Discovered novel laccase and peroxidases enzymes using state-of-the-art metagenomics and bioinformatics techniques. Discovered and engineered novel thermostable cellulase and hemicellulase enzymes and evaluated their activities and efficacy in various industrial biofuel processes. Core member of team interacting with engineers, chemists, and biologists. Project Manager for the EU METAEXPLORE consortium Discovered numerous novel cellulase, xylanase, and laccase genes/enzymes Led the research efforts to enzymatically characterize the novel recombinant enzymes and tested compatibility with biofuels industrial processes Developed metagenomics techniques to identify and develop novel industrial enzymes

Biomedicum Helsinki is a world-class research institute affiliated with the University of Helsinki. It is located within the historic Meilahti campus of the University of Helsinki.

* Demonstrated that muscle specific tyrosine kinase (MuSK) kinase-dependent and -independent signaling mechanisms regulate development of the mammalian neuromuscular junction (NMJ) by modulating acetylcholine receptor (AChR) clustering in myotubes. * Developed T7 phage display assay to identify novel MuSK-interacting proteins * Cloned and characterized novel MuSK-interacting protein, PAUL * Led efforts to identify novel MuSK signaling mechanisms

At Illumina, our goal is to apply innovative technologies and revolutionary assays to the analysis of genetic variation and function, making studies possible that were not even imaginable just a few years ago. These studies will help make the realization of personalized medicine possible. With such rapid advances in technology taking place, it is mission critical to have solutions that are not only innovative, but flexible, scalable, and complete with industry-leading support and service. As a global company that places high value on collaborative interactions, rapid delivery of solutions, and prioritizing the needs of its customers, we strive to meet this challenge. Illumina's innovative, array-based solutions for DNA, RNA, and protein analysis serve as tools for disease research, drug development, and the development of molecular tests in the clinic.

Graduated with Honors in Chemistry and Psychology. Minored in Biology. - Active in student government, serving as President of Teter Quad student association. - Accepted to the School of Music as flutist. - Honors thesis titled "Hemispheric Processing of Phase-variant Visual Vernier Stimuli." Activities and Societies: Student government

Graduated with Ph.D. in Neuroscience."]